New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—

Revenue to profit Fiscal 2026, year to Jun 30, 2026

It lost $38.7M on $1.9M of revenue: $2057.51 for every $100. What is an income statement?

Revenue to profit, in millions of dollars and as a share of revenue
Revenue1.9100.0%
Cost of revenue−1.7−90.5%
Gross profit0.29.5%
Research & development−33.9−1805.1%
Selling, general & admin−12.6−672.8%
Other operating costs+7.8416.8%
Operating income−38.5−2051.5%
Other income, net−0.1−4.1%
Income tax0.0−2.0%
Net income−38.7−2057.5%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, three years
FY24FY25FY26
Revenue$0.0B$2.4M$1.9M
Operating income−$31M−$25M−$39M
Net income−$31M−$25M−$39M
Net margin (right axis)−16027.0%−1055.3%−2057.5%
Jun '24 Jun '25 Jun '26
Revenue
0.20 2.35 1.88
Revenue Growth
— 1,099.29% (20.16%)
Gross Profit
0.20 0.03 0.18
Operating Income
(30.96) (24.72) (38.54)
EBT
(31.38) (24.76) (38.62)
Income after Tax
(31.44) (24.83) (38.65)
Net Income Common
(31.44) (24.83) (38.65)
EPS (Diluted)
(24.41) (3.58) (3.65)
Shares (Diluted, Weighted)
1.29 6.94 10.24
Gross Margin
100.00% 1.08% 9.52%
EBIT Margin
(15,779.92%) (1,050.63%) (2,051.48%)
Net Profit Margin
(16,027.01%) (1,055.27%) (2,057.51%)
Free Cash Flow Margin
(7,679.71%) (926.07%) (1,906.94%)
EBITDA
(28.91) (23.04) (36.70)
EBIT
(30.96) (24.72) (38.54)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 2, 2026